Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02958865 · ClinicalTrials.gov registry record · Phase 2
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 319
- Enrollment target
- 20
- Study locations
NCT02958865: Completed Phase 2 study of Ulcerative Colitis, sponsored by Pfizer.
NCT02958865 is a Phase 2 study of Ulcerative Colitis that has completed, run by Pfizer. The registered enrollment target is 319 participants, below the 2,055-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02958865, a Phase 2 study of Ulcerative Colitis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 319 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
Primary Outcome
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicates more severe disease activity and lower score denotes improvement of disease activity as measured by the total Mayo score.
Conditions Studied
Interventions
- DRUG PF-06651600
- DRUG PF-06651600 or Placebo
- DRUG PF-06700841 or Placebo
- DRUG PF-06700841
Study Locations (20)
Florida
- West Coast Endoscopy Center - Clearwater
- University of Miami Hospital and Clinics - Miami
- University of Miami Hospital - Miami
- Millenia Surgery Center - Orlando
- HMD Research LLC - Orlando
- Orlando Gastroenterology, PA - Orlando
California
- Long Beach Clinical Trials Services Inc. - Long Beach
- Southern California Research Institute Medical Group/West Gastroenterology Medical Group/Airport En- - Los Angeles
- Clinical Application Laboratories, INC. - San Diego
- San Diego Endoscopy Center - San Diego
- Medical Associates Research Group - San Diego
Connecticut
- Bristol Hospital - Bristol
- Connecticut Clinical Research Institute - Bristol
- Central Connecticut Endoscopy Center - Plainville
Alabama
- Dothan Surgery Center - Dothan
- Gut P.C., dba Digestive Health Specialists of the Southeast - Dothan
Colorado
- Front Range Endoscopy Center - Colorado Springs
- Peak Gastroenterology Associates - Colorado Springs
Illinois
- Southwest Gastroenterology - Oak Lawn
Maryland
- Chevy Chase Endoscopy Center - Chevy Chase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2021-05-10 |
| Phase | Phase 2 |
What the finished NCT02958865 record still lists
NCT02958865 is an interventional study that assigns participants to a tested intervention. The registered 319 participants enrollment target is mid-sized for trials with a published cap, below the 2,055-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 4 interventions - of which PF-06651600 is the first listed.
NCT02958865 names 20 study sites across 7 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02958865 about?
NCT02958865 is a clinical study titled "Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis". The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
What is the current status of trial NCT02958865?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 319 participants. The study started on 2017-02-03. Estimated completion is 2021-05-10.
What conditions does trial NCT02958865 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT02958865?
The interventions under investigation include: PF-06651600 (DRUG), PF-06651600 or Placebo (DRUG), PF-06700841 or Placebo (DRUG), PF-06700841 (DRUG).
Who is sponsoring clinical trial NCT02958865?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02958865 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02958865's enrollment target sits among peer trials
319 32nd of 122 higher than 91 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05377996 · 319 participants · Phase 1
A Study of XMT-1660 in Participants With Solid Tumors
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI